Related Experiment Videos
[Immunosuppressive treatment in multiple sclerosis].
T V Oliveira1, A M Gorz-Reinhardt, C M Gracia
1Unidade de Neurologia Clínica, Hospitais Nossa Senhora das Graças, Brasil.
Arquivos De Neuro-Psiquiatria
|September 1, 1992
Summary
Immunosuppressive therapy for multiple sclerosis (MS) showed potential in halting disability progression. While side effects varied among drugs like prednisone and azathioprine, the study supports its use in select rapidly evolving MS cases.
Area of Science:
- Neurology
- Immunology
- Clinical Pharmacology
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease.
- Immunosuppressive therapies have been explored for MS management.
- Evaluating long-term efficacy and tolerability is crucial for treatment decisions.
Purpose of the Study:
- To assess the efficacy and tolerability of immunosuppressive treatments for multiple sclerosis.
- To analyze outcomes of various immunosuppressive agents used between 1982-1990.
- To determine if immunosuppression can halt disability progression in MS patients.
Main Methods:
- An open, retrospective, uncontrolled study design.
- Evaluation of 42 patients with clinically definite multiple sclerosis.
- Assessment of drug tolerability and efficacy using objective scales over at least 2 years follow-up.
Main Results:
- Side effects were observed in 54% of azathioprine users and 83% of prednisone users, leading to dose changes or withdrawal.
- Methylprednisolone showed better tolerability (12% side effects) compared to other agents.
- Efficacy data from 15 patients suggested immunosuppression could arrest disability progression.
Conclusions:
- Immunosuppressive therapy may be beneficial in selected multiple sclerosis cases with rapidly worsening neurological deficits.
- Tolerability varies significantly among different immunosuppressive drugs.
- Further controlled studies are warranted to confirm efficacy and optimize treatment regimens.